Determination of Prostate-specific Antigen in Capillary Blood (PSA-Cap)
PSA-Cap
1 other identifier
observational
200
1 country
1
Brief Summary
The aim of the PSA-Cap study is to test the comparability of measurements of total PSA in serum from venipuncture and in serum from capillary blood using anonymized diagnostic blood samples from patients. Furthermore, a stability test of the samples is carried out after storage at room temperature for 24, 72/96 and 168 hours. Particular attention is paid to the comparability of the measurement results and the influence of the transportation time.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2024
CompletedFirst Submitted
Initial submission to the registry
October 2, 2024
CompletedFirst Posted
Study publicly available on registry
October 3, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
October 31, 2024
CompletedOctober 3, 2024
October 1, 2024
4 months
October 2, 2024
October 2, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Accuracy of PSA measurement in capillary blood vs. venous blood
After 0 h, 1 d, 3/4 d and 7 d
Secondary Outcomes (1)
PSA stability in serum fraction of both samples (capillary and venous)
After 0 h, 1 d, 3/4 d and 7 d
Interventions
PSA Testing in venipunctate and capillary blood
Eligibility Criteria
Male patients between the ages of 40 and 70 who receive a PSA test as part of their routine examination
You may qualify if:
- Men aged from 45 to 70 years
- Informed consent for PSA measurement for prostate cancer screening
You may not qualify if:
- Patients unable to give consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Klinik für Urologie, Universitätsklinikum Düsseldorf
Düsseldorf, North Rhine-Westphalia, 40225, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Oberarzt
Study Record Dates
First Submitted
October 2, 2024
First Posted
October 3, 2024
Study Start
June 1, 2024
Primary Completion
September 30, 2024
Study Completion
October 31, 2024
Last Updated
October 3, 2024
Record last verified: 2024-10
Data Sharing
- IPD Sharing
- Will not share